Short answer
Ispire Technology Inc. (ISPR) filed its fiscal 2026 10-K annual report with the SEC on Sep 15, 2026. It reported revenue of $96M (−24.7% year over year) and net income of −$33M.
- Top risk flagged: Regulatory risk: FDA PMTA compliance and enforcement for nicotine ENDS under Family Smoking Prevention and Tobacco Control Act; costly $1M+ per PMTA application
FY2026 key financial metrics · XBRL
- Revenue
- $96M
- −24.7% YoY
- Net income
- −$33M
- +15.4% YoY
- Operating margin
- -33.9%
- −4.3 pp YoY
- Gross margin
- 12.8%
- −5.0 pp YoY
- EPS (diluted)
- −$0.58
- +15.9% YoY
- ROE
- 113.5%
- +6602.8 pp YoY
- Operating cash flow
- −$569,416
- +92.3% YoY
Source: XBRL data from the Ispire Technology Inc. (ISPR) FY2026 10-K on SEC EDGAR. USD.
Ispire Technology Inc. FY2026 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: design, R&D, commercialization, sales of vaping hardware for nicotine and cannabis under Aspire and Ispire brands globally
- New products: proprietary Ispire ONE™ technology introduced June 2023; development started on G-Mesh porous glass coil tech marketed as “Silica Series”
- Strategic shift: major expansion of owned manufacturing in Malaysia, commenced in Feb 2024 with 6 lines, aiming to add 70 new lines over next 12 months
- Quantitative highlights: revenue declined 25% to $96M in 2026 from $127M in 2025; OEM/ODM share rose to 44.5% of e-cigarette revenue in 2026 from 40.2% in 2025; employee count 88 as of Sept 2026
- Noteworthy fact: Formation and FDA engagement of IKE joint venture with 40% ownership to develop age-gating tech for e-cigarettes, including PMTA submissions and recent FDA draft guidance linking DAR tech to flavored ENDS authorization
Management Discussion & Analysis
- Revenue $96.0M, down 24.7% YoY from $127.5M; US sales fell $17.4M, Europe down $12.7M due to regulatory challenges
- Gross margin 12.8% vs 17.8% prior year; gross profit $12.3M vs $22.6M, margin decline due to pricing pressure, lower cannabis product mix, and $2.8M inventory write-down
- Europe segment best performer with $61.4M revenue (63.9%), North America weakest at $15.1M (15.8%) reflecting tightening sales strategy
- Operating expenses down 25.8% to $44.9M driven by cuts in marketing (-40.5%) and G&A (-36.2%); net loss improved to $33.2M from $39.2M, loss per share $0.58 vs $0.69
- Operating cash flow usage reduced to $0.6M vs $7.4M; invested $3.1M mainly in joint venture and capex; $1.3M repaid on borrowings; management expects current cash and operations to fund next 12 months but additional financing may be needed if growth accelerates or conditions worsen
Risk Factors
- Regulatory risk: FDA PMTA compliance and enforcement for nicotine ENDS under Family Smoking Prevention and Tobacco Control Act; costly $1M+ per PMTA application
- Geopolitical risk: U.S. tariffs on Chinese imports at 35% and Malaysian imports at 19%, affecting Shenzhen Yi Jia product costs, a major supplier
- Operational risk: Dependence on Shenzhen Yi Jia (95% owned by CEO) for manufacturing; risks in scaling new Malaysian facility and controlling quality
- Competitive risk: Pressure from largest producer Smoore International Holdings Limited and technological innovation demands in vaping market
- Financial risk: Majority stock ownership and supplier control by CEO Tuanfang Liu pose conflicts of interest impacting pricing and governance
Generated from the filing text; verify against the original. How to read a 10-K
Other Ispire Technology Inc. annual reports
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.